THANK YOU FOR SUBSCRIBING
ExsoMed Corporation's solutions raise the standard of care in hand surgery by providing state of the art surgical tools that simplifies use in the operating room, lowers the global cost of care, and improves outcomes so that patients can get back to life faster.
FREMONT, CA: ExsoMed Corporation, a privately held U.S.-based medical device company providing orthopedic surgeons with innovative solutions in hand surgery, announced the completion of its second round of financing. This investment round, comprised entirely of private investors, included participation from both existing investors and new individuals.
This financing round, at an increased valuation from its seed funding round, builds on a year characterized by a rapidly growing surgeon user base, significant adoption of the company's flagship product INnate™ as the new standard for minimally invasive fixation of metacarpal fractures, and increasing market momentum in the hand surgery space.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
ExsoMed is a privately held medical device company providing orthopedic surgeons with innovative solutions in hand surgery. Their solutions raise the standard of care in hand surgery by providing state of the art surgical tools that simplifies use in the operating room, lowers the global cost of care, and improves outcomes so that patients can get back to life faster.
"We are gratified by the market's enthusiasm for ExsoMed, not just from our individual investors, but also from our expanded distribution network and surgeon users," said Daniel Mickelsen, ExsoMed's Chief Operating and Financial Officer. "This influx of capital ensures that ExsoMed will support our rapid growth and continue to deliver innovation to the hand surgery market, all while creating value for our shareholders."
Proceeds from the financing will further drive ExsoMed's core business, expand the company's commitment to surgeon education, and fuel upcoming product launches scheduled for Q4 2020 and early 2021.
More in News